Avadel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Avadel Pharmaceuticals has a total shareholder equity of $70.3M and total debt of $35.5M, which brings its debt-to-equity ratio to 50.5%. Its total assets and total liabilities are $157.5M and $87.2M respectively.
Key information
50.5%
Debt to equity ratio
US$35.49m
Debt
| Interest coverage ratio | n/a |
| Cash | US$71.38m |
| Equity | US$70.29m |
| Total liabilities | US$87.23m |
| Total assets | US$157.52m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AWK's short term assets ($125.8M) exceed its short term liabilities ($44.6M).
Long Term Liabilities: AWK's short term assets ($125.8M) exceed its long term liabilities ($42.6M).
Debt to Equity History and Analysis
Debt Level: AWK has more cash than its total debt.
Reducing Debt: AWK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AWK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AWK has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.5% each year